Kornimate/medical-research-clean huggingface dataset:
detecting chronic subdural hematoma with microwave technology

Conditions: Chronic Subdural Hematoma; Healthy Volunteers

Summary: an open study evaluating the sensitivity and specificity of a microwave-based device, medfield strokefinder md100, to detect chronic subdural hematoma, by comparing measurements on patients recruited for surgery of chronic subdural hematoma to an age- and gender-matched group of healthy volunteers.

this open study will enroll patients admitted for surgery of chronic subdural hematoma at the department of neurosurgery at sahlgrenska university hospital and compare them to measurements of healthy volunteers. patients will be asked to participate in the study, as early as possible after admission. after physical examination, checking the inclusion/exclusion criteria, and after informed consent has been acquired, the microwave-based measurement will be performed. the diagnostic procedure is estimated to take 30 min whereof total subject measurement time will be less than five minutes. healthy volunteers will be recruited in parallel and the same procedure as for the patients will be followed. safety will be followed throughout the study, and a safety follow-up will be performed 12 hours after the microwave-based investigation is finalized. to avoid measurement bias all measurements, for both patients and healthy volunteers, will be performed by the same operator.

Eligibility criteria:
inclusion criteria: * patient admitted for surgery of chronic subdural hematoma. * a ct scan of the patient has been performed, within the latest 96 hours. * the patient should be able to have a normal conversation and understand the information about the study, corresponding to glasgow coma scale (verbal response) of 5. * patient/healthy volunteer should be ≥ 18 years of age. * the patient/healthy volunteer has signed a written informed consent. exclusion criteria: * females who are pregnant or breast feeding women. * patient/healthy volunteer has a shunt or other foreign object implanted in the brain. * patient/healthy volunteer participating in any other clinical study that could interfere with the result in the ongoing study.
potential impact of polycystic ovarian syndrome on protein modifications and accumulation

Conditions: Polycystic Ovarian Syndrome (PCOS); Insulin Resistance; Overweight; Obese

Summary: a goal of this study is to use a novel methodology to determine whether insulin resistance in women with polycystic ovary syndrome (pcos) is related to the accumulation of proteins with modifications. this could lead to future research to determine if these modifications interfere with their proper function. additionally, the investigators will determine how protein quality is affected by exercise training. aerobic exercise enhances the endogenous oxidant buffering systems which may minimize oxidative damage to proteins. the investigators propose that aerobic exercise minimizes the accrual of modified proteins by increasing the synthesis of new proteins, but also by increasing the degradation and removal of old and damaged proteins. based on our previous studies the investigators observed that insulin affects plasma protein synthesis and aerobic exercise improves insulin sensitivity not only in muscle but also in liver. the investigators therefore propose that aerobic exercise and related increase in insulin sensitivity (and decline in insulin levels) will reduce accumulation of old and modified skeletal muscle and plasma proteins leading to improved function.


Eligibility criteria:
inclusion criteria: 1. bmi between 25 kg/m2 and 40 kg/m2 2. fasting blood glucose \< 126 mg/dl 3. diagnosed with pcos as outlined by the rotterdam criteria 4. insulin resistant as determined by a 3 hour oral glucose tolerance test exclusion criteria: 1. serum creatinine ≥1.5 mg/ dl. 2. serum transaminase elevation ≥ 3 times the upper limit of normal range 3. use of systemic glucocorticoids 4. use of oral anticoagulation 5. pregnancy

Keywords: polycystic ovarian syndrome (pcos) insulin resistance overweight, obese women protein metabolism post translational modifications
evaluation of non-invasive hemoglobin in trauma patients

Conditions: Trauma

Summary: this is a prospective, non-blinded, non-randomized, interventional study of the masimo pulse oximeter and sensors in a trauma setting

the study aimed to evaluate sphb's ability to detect critical drops in a trauma population

Eligibility criteria:
inclusion criteria: * estimated 16 years of age or older or greater than or equal to 50 kg body weight if age unknown. * level 1 (highest trauma activation) status at the time of arrival to emergency department (ed). * expected to be admitted to the icu/imu for in hospital care. exclusion criteria: * moribund patients with devastating injuries and expected to die within one hour of ed admission. * prisoners, as defined as those who have been directly admitted from a correctional facility (a free living individual who is under police observation as a suspect will remain in the study until hospital discharge). * obvious pregnancy in the ed. * received greater than 5 minutes of cardiopulmonary resuscitation (cpr) in the pre-arrival or hospital setting. * has, on the ring, middle and index fingers of both hands, any of the following: finger deformities, injuries, including burns, scar tissue or infection, or any material that may interfere with sensor application or trans-illumination of the site. * has significant bilateral trauma to the arms or forearms.
safety and efficacy following repeat-dose of evinacumab (anti-angptl3) in patients with severe hypertriglyceridemia (shtg) at risk for acute pancreatitis

Conditions: Severe Hypertriglyceridemia (sHTG)

Summary: the primary objective is to determine the change in triglyceride (tg) levels following 12 weeks of repeated intravenous (iv) doses of evinacumab.


Eligibility criteria:
key inclusion criteria: 1. previous documentation in the patient's medical records of a fasting serum tg measurement ≥ 1000 mg/dl (11.3 mmol/l) on more than 1 occasion, and all fasting tg values ≥500 mg/dl (5.6 mmol/l) at screening 2. history of a hospitalization and diagnosis of acute pancreatitis in the past 10 years 3. on stable lipid-modifying diet with or without medications (eg, statins, niacin, omega-3 fatty acids). lipid-modifying diet and doses of medications should be stable for at least 4 weeks (6 weeks for fibrates, 8 weeks for pcsk9 inhibitors) prior to screening 4. body mass index (bmi) of 18-40 kg/m2 key exclusion criteria: 1. a hospital or clinic discharge diagnosis of acute pancreatitis within 12 weeks of screening 2. lipid apheresis or plasma exchange treatment within the last 4 weeks or plans to undergo apheresis or plasma exchange during the time frame of the study 3. history of class 3/4 heart failure at any time in the past, or hospitalization for heart failure, diagnosis of a myocardial infarction, stroke, transient ischemic attack (tia), unstable angina, coronary artery bypass surgery (cabg), percutaneous coronary intervention (pci), carotid surgery/stenting within 3 months before the screening visit 4. history of bleeding disorders, esophageal varices, heparin induced thrombocytopenia, or contraindications to receiving heparin (eg, allergic reaction to heparin) 5. previous treatment with glybera® in the past 5 years or treatment with lomitapide or mipomersen in the past 6 months 6. pregnant or breast feeding women note: other protocol defined inclusion/exclusion criteria may apply
non-surgical peridontal treatment on cardiovascular risk markers

Conditions: Cardiovascular Risk Markers; Chronic Periodontitis

Summary: the study evaluates the influence of non-surgical mechanical periodontal treatment in patients with severe chronic periodontitis on inflammatory markers related to risk for cardiovascular diseases

a total of 80 non-smokers with systemically healthy, including 40 patients with severe chronic periodontitis and 40 periodontally health subjects were included into the present study. the probing depth, clinical attachment level, plaque index, gingival index and blood samples were collected at baseline and at the 3rd months after treatment and the serum levels of asymmetric dimethylarginine (adma), endothelial nitric oxide synthase (enos), homocysteine (hcy), monocyte chemoattractant protein-1 (mcp-1) were determined with enzyme-linked immunosorbent assay (elisa).

Eligibility criteria:
inclusion criteria: clinical diagnosis of severe chronic periodontitis clinical diagnosis of periodontal health exclusion criteria: systemic diseases such as diabetes, cardiovascular disease periodontal treatment within the previous year drugs such as systemic steroids, non-steroidal anti-inflammatory drugs, immunosuppressants, hormone drugs, contraceptives, anticoagulants, cholesterol regulating drugs, systemic antibiotics, antioxidants within the previous 3 months pregnant or lactating consumed alcohol smoker

Keywords: asymmetric dimethylarginine endothelial nitric oxide synthase homocysteine monocyte chemoattractant protein-1
the lifestyle education about nutrition for diabetes (legend) study

Conditions: Type 2 Diabetes

Summary: this study is being completed to compare two dietary approaches for participants with type 2 diabetes. this research will test whether a very low-carbohydrate or a plate-method diet better improves outcomes for blood glucose control and body composition for patients with type 2 diabetes that follow one of these approaches for 12 months. participants that meet screening and eligibility will be randomized to one of the two diets. in addition to the diet, study specific visits and assessments will be performed at various timepoints.


Eligibility criteria:
inclusion criteria: * diagnosis of type 2 diabetes, with current hba1c \> 6.5% and \< 12% (self-reported and then measured at screening) * ability to speak english (this is a group-based intervention) * ability to engage in light physical activity * willingness to be randomized to either type of diet exclusion criteria: * unable to provide informed consent * substance abuse, mental health, cognitive, or medical condition that would, in the opinion of the investigators, make it difficult for the individual to take part in the intervention, may alter key outcomes, or may require important diet modifications and includes conditions such as hypercalcemia or thyroid dysfunction * pregnant or planning to become pregnant in the next 12 months, or currently breastfeeding (pregnancy and breastfeeding require modifications to the intervention's dietary approaches) * current use of weight loss medications (this is likely to alter weight outcomes and may alter other measures) * history of weight loss (bariatric) surgery or plans for bariatric surgery in the next year * currently enrolled in a weight loss program or have unalterable plans to enroll in one of these programs in the next year * vegan or vegetarian * unwilling or unable to participate in study measurements and group classes * current use of systemic steroids (self-reported in screening survey; oral or iv systemic steroids excluded. injected steroids may be permitted depending on frequency and timing of injections with regard to lab assessments (minimum of 2 weeks between injection and blood tests)) * weight above 400 pounds (weight limit for dual-energy x-ray absorptiometry (dexa) scans) * history of multiple or recent (within the last four years) kidney stones * currently following a very low-carbohydrate diet * unwilling to stop an sglt2 inhibitor medication if the participant were to be randomized to the very low-carbohydrate diet

Keywords: very low-carbohydrate diet moderate-carbohydrate plate-method diet nutrition therapy
frail elderly subjects - evaluation and follow-up

Conditions: Frail Elderly People

Summary: this was a prospective multicenter cohort study of elderly people admitted to medical wards via emergency departments. subjects were followed up to 36 months. it aimed to study the inhospital pathways and adverse geriatric outcomes. in all, 1306 subjects were included : 85+/-5 years, and mainly women (65%).

the safes cohort was formed within a national research program (funded by the french ministry of health) into the recruitment of emergency units in nine teaching hospitals. all nine centres had a geriatric ward. the inclusion of subjects ran from march 1st 2001 to january 17th 2002. to be eligible, patients were to be 75 or over, to have been hospitalised in a medical ward in the same hospital as the emergency unit to which they were initially admitted. subjects were not eligible if hospitalisation was into intensive care or surgery, or if admission did not occur after admission to the emergency unit. every day in each centre, patients admitted to the emergency unit were registered. from the list thus obtained, patients were selected by random draw stratified at two levels: in each week, 5 days were selected randomly, and for each of these days, two patients were chosen randomly. next, each patient was visited by a specialist in geriatrics familiar with the survey procedures. in the course of this interview, patients were informed about the study, prior to signing the consent form. if the clinical status and/or the cognitive status of the patient did not enable informed consent, the interviewer referred to the subject's representative. follow-up was by telephone interview after the 1st, 8th and 21st month and by face-to-face interviews after the 5th, 12th, 18th, and 24th month following the initial hospitalisation. several outcome have been studied.

Eligibility criteria:
inclusion criteria: * age of 75 years or over * admitted to medical ward via emergency department * consent to participate exclusion criteria: * not hospitalised after emergency department stay * admitted to surgery or intensive car unit * died before signing informed consent form
green tea extract in treating patients with metastatic prostate cancer that has not responded to hormone therapy

Conditions: Prostate Cancer

Summary: rationale: green tea extract contains substances that may slow the growth of certain cancers and may prevent the development of new cancers. purpose: phase ii trial to determine the effectiveness of green tea extract in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.

objectives: i. determine the effectiveness and toxicity of green tea extract in patients with androgen-independent metastatic prostate cancer. ii. determine the response rate and response duration in patients treated with this regimen. iii. determine whether a decline in prostate-specific antigen (psa) coincides with evidence of disease regression in these patients. outline: patients receive oral green tea extract six times daily for 4 months. patients with a 50% decline in psa, complete or partial response, or stable disease after 4 months continue treatment in the absence of disease progression or unacceptable toxicity. patients with disease progression after 4 months receive no further treatment. patients are followed every 3 months for 5 years or until disease progression. if disease progression, patients are followed every 6 months for 5 years.

Eligibility criteria:
disease characteristics: clinically proven androgen-independent metastatic prostate cancer radiological, physically palpable, and/or biochemical evidence of progression increase in psa after orchiectomy or hormonal treatment no symptoms directly attributable to metastatic disease no cns metastases or carcinomatous meningitis patient characteristics: age: 18 and over performance status: ecog 0-2 life expectancy: at least 12 weeks hematopoietic: not specified hepatic: bilirubin no greater than 1.5 mg/dl renal: creatinine no greater than 2 times upper limit of normal cardiovascular: no uncontrolled high blood pressure no unstable angina no symptomatic congestive heart failure no uncontrolled cardiac arrhythmias no myocardial infarction in past 6 months other: no other malignancy within the past 5 years except basal cell skin cancer no uncontrolled diabetes mellitus or inability to tolerate high sugar content of green tea at discretion of oncologist no other medical or psychiatric conditions that would preclude study prior concurrent therapy: biologic therapy: at least 4 weeks since prior immunotherapy chemotherapy: at least 4 weeks since prior chemotherapy no concurrent chemotherapy endocrine therapy: at least 4 weeks since prior flutamide or megestrol at least 6 weeks since prior longer-acting hormonal agents such as bicalutamide at least 4 weeks since prior hormonal therapy, except luteinizing hormone- releasing hormone agonist no concurrent hormonal therapy, including corticosteroids for cancer treatment radiotherapy: no concurrent radiotherapy surgery: see disease characteristics other: no other concurrent investigational agents

Keywords: stage iv prostate cancer recurrent prostate cancer
comparison between hand-acupuncture and electro-acupuncture stimulation in the treatment of menopause

Conditions: Menopause; Puncture Site Reaction

Summary: main objective: to compare the effects of hand-acupuncture and electro-acupuncture stimulation on the baking heat symptoms of menopause secondary objective: to evaluate the safety and acceptability of hand acupuncture and electroacupuncture stimulation


Eligibility criteria:
inclusion criteria: 1. in past of 12 months in, menstrual cycle not rules, menstrual ahead of or wrong hou ≥ 7 days (menopause transition period early); in past of 12 months in, at least shedding had 2 a menstrual cycle, or amenorrhea over 60 days, but ≤ november (menopause transition period late); last once menstrual to stopped by hou 3 years within (menopause 3 years within patients) 2. menopause-related symptoms: baking heat, sweating, insomnia, migraines,irritability, sore vagina, sexual intercourse and so on 3. 40-55 years 4. baseline scorch score ≥ 6 points 5. without hormone therapy indications for mandatory, such as during menopause, osteoporosis mobility 6. volunteered for this study, and sign the consent form exclusion criteria: 1. test within 3 months before the menstrual cycle rules 2. nearly 4 weeks applied estrogen, ssris, soy isoflavones, progesterone, vitamin e, or black cohosh 3. diameter greater than 4cm fibroid ovarian cyst, ovarian or after hysterectomy 4. disease history of chemotherapy or who are undergoing chemotherapy 5. unexplained vaginal bleeding 6. coagulation disorders or taking anticoagulant drugs such as warfarin, heparin 7. suffered from skin diseases like eczema, psoriasis, etc 8. severe hepatic and renal insufficiency 9. yet controlled high blood pressure, diabetes, or thyroid disease 10. diabetic nerve damage, cancer and mental illnesses (including depression) 11. wishes are in pregnancy or pregnancy or breastfeeding 12. long-term use of sedatives or antidepressants 13. long-term smoking and alcoholism 14. installed pacemaker or artificial joints

Keywords: acupuncture electro acupuncture menopause
highlighting the benefits of therapeutic gardens in alzheimer's disease by 18f-fdg cerebral pet /ct

Conditions: Alzheimer Disease

Summary: the alzheimer's plan 2008-2012 allowed the installation of therapeutic gardens for the structures welcoming patients with alzheimer's disease (ad) . the physical, psychological and social benefits are the improvement of the state of health and overall well-being. there is a positive role in social interactions for patients with ad who can walk in the therapeutic gardens. indeed, this promotes meetings with caregives and other people. using the garden decreases the stress level in patients (ulrich). the therapeutic garden named "art, memory and life" in nancy is based on art, nature and regional culture. this garden can break with the "artificial" framework of care services often perceived as stressful. in the garden, people walk around and have an experience that could improve self-image perception. a clinical study with 2 groups of ad patients hospitalized in ucc or cognitive behavioral unit took place in nancy. the evaluation of the qcs (questionnaire on self-awareness) was carried out at the beginning and at the end of the study, * a group of patients went into the garden: the qcs score increased * a group of patients did not go to the garden (they remained in ucc): the qcs score decreased


Eligibility criteria:
inclusion criteria: * patient with ad in the mild to moderate stage, followed at the memory and resource center (cmrr) (mms 15-23) and having had a 18f-fdg pet-ct (positon emission tomography) scan in routine care having a companion for the duration of the study . * patient with a neuropsychological assessment (moca, do80, bref, had) of less than 3 months. (if the last neuropsychological assessment dates from more than 3 months, these tests are carried out in routine care during the consultation was proposed and the consent obtained) * symptomatic treatment of ad (anticholinesterase or memantine) if prescribed, at a stable dose for 1 month, stable psychotropic treatment for 1 month * person affiliated with a social security scheme or beneficiary of such a scheme. * patient over 18 years old. * person received complete information on the organization of the research and having signed their informed consent. exclusion criteria: * patient who did not have biomarkers identified by lumbar puncture * patient unable to perform a cerebral 18f-fdg pet-ct scan (lying position for more than 20 minutes) * patient unable to follow the therapeutic program of the garden. * woman of childbearing age whitout effective contraception. * pregnant woman or nursing mother. * person referred to in articles l. 1121-5, l. 1121-7 and l1121-8 of the public health code. * persons deprived of their liberty by a judicial or administrative decision, persons subject to psychiatric treatment under articles l. 3212-1 and l. 3213-1
randomized implementation of primary hpv testing in the organized screening for cervical cancer in stockholm

Conditions: High-grade Cervical Intraepithelial Neoplasia; Invasive Cervical Cancer

Summary: the purpose is to evaluate whether implementation of primary human papillomavirus (hpv) screening in the screening programme for cervical cancer improves the programme in terms of better cancer protection and better cost efficiency.

primary hpv screening is a method with higher sensitivity than cytology for detection of high-grade cervical intraepithelial neoplasia, which is the precursor of cervical cancer. in particular, hpv test is a better test for revealing adenocarcinomas, since these cancers often show a normal cytology. cytology is less effective in older women, and screening with cytology in women over 60 has no documented effect. today a large part of cervical cancer develop in women older than 60, to whom no screening is offered. the prevalence of hpv is around 4% in this age group. since we know that testing negative for hpv gives a better long-term protection against cervical cancer compared to cytology, primary screening for hpv in 60-year old women would give a longer lasting protection in this high-risk group compared with today. hpv screening is most cost effective above 35 years of age. the reason for this is that hpv is less prevalent at age 35 than in younger women and also because cervical cancer seldom develops before this age. since the hpv test has a negative predictive value (npv) of almost 100% this could lead to longer screening intervals, which would be improve cost-effectiveness.

Eligibility criteria:
inclusion criteria: women between the age 30 and 64 years resident in the stockholm-gotland region. no exclusion criteria.

Keywords: hpv testing primary screening cervical cancer